ARCHIVES

Chabner : Opportunity To Set Own Agenda Reason For Leaving

This article is from The Cancer Letter archive.

Vol. 20 No. 41 | October 28, 1994

Download PDF Visit The Full Archive

Related Articles

FDA Forms Office of Combination Products;

January 10, 2003

Neulasta Reduces Incidence Of Febrile Neutropenia

February 22, 2013

Groups Point to NCI Restrictions As Source Of Problems, Discuss Prioritizing Trials

July 11, 2003

Working Group Considering formal Cap On size of Cancer Center Support Grants

March 22, 1996

Pryce Introduces Bill To Reimbuse For Orally Administered Cancer Drugs.

May 4, 2001

Second-Generation CML Drugs Show Promise For Frontline

December 26, 2008